5.31091

Porcn Inhibitor IV, LGK974

• Synonim(y): Porcn Inhibitor IV, LGK974, 2-(2ʹ,3-Dimethyl-2,4ʹ-bipyridin-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide, Wnt Pathway Inhibitor XXIII, LGK-974
• Wzór empiryczny (zapis Hilla): C₂₃H₂₀N₆O
• Numer CAS: 1243244-14-5
• Masa cząsteczkowa: 396.44
• Kod UNSPSC: 12352200
• NACRES: NA.77

Właściwości

• Próba: ≥97% (HPLC)
• Poziom jakości: 100
• Postać: powder
• producent / nazwa handlowa: Calbiochem^®
• warunki przechowywania: OK to freeze; protect from light
• kolor: tan
• rozpuszczalność: DMSO: 50 mg/mL
• temp. przechowywania: 2-8°C
• InChI: 1S/C23H20N6O/c1-15-9-17(12-28-23(15)18-5-6-25-16(2)10-18)11-22(30)29-21-4-3-19(13-27-21)20-14-24-7-8-26-20/h3-10,12-14H,11H2,1-2H3,(H,27,29,30)
• Klucz InChI: XXYGTCZJJLTAGH-UHFFFAOYSA-N

Opis

Opis ogólny

A cell-permeable C59 (Cat. No. 500496) structural analog that potently inhibits TM3 cellular Wnt pathway activation-dependent transcription by blocking Wnt secretion from co-cultured L-cells (IC₅₀ from 50 pM to 1.1 nM using Wnt1/2/3/3a/6/7a/9a L-cell transfectants) via direct porcupine (Porcn), but not Wntless, affinity interaction. Shown to inhibit Wnt-dependent proliferation of head and neck squamous cell carcinoma (HNSCC) line HN30 (IC₅₀ = 0.3 nM in 48 h colony formation assay), but not the growth of 293T even at concentrations as high as 20 µM. In mice & rats receiving therapeutic LGK974 oral dosages (up to 5 mg/10 mL/kg/d), a delayed tissue Wnt signaling suppression (max inhibition 7 to 10 h post dosing) is seen due to pre-existing Wnt in tissue, followed by a full recovery of tissue Wnt signalling at 24 h upon drug clearance. The periodic daily inhibition/recovering cycle is shown to result in tumor regression in mice & rats harboring tumors derived from human HNSCC HN30 or tumor fragments from murine mammary tumor virus (MMTV)-Wnt1 transgenic mice, while allowing Wnt signaling-dependent normal tissue homeostasis. Overdosing is reported to result in loss of intestinal epithelium in rats receiving 14 consecutive 20 mg/kg daily oral dosages.

A cell-permeable C59 (Cat. No. 500496) structural analog that potently inhibits Wnt secretion from L-cell Wnt1/2/3/3a/6/7a/9a transfectants (IC₅₀ from 50 pM to 1.1 nM) via direct porcupine (Porcn), but not Wntless, affinity interaction. Shown to inhibit the proliferation of head and neck squamous cell carcinoma (HNSCC) line HN30 (IC₅₀ = 0.3 nM), but not 293T even at a high concentration of 20 µM. In mice & rats receiving therapeutic LGK974 oral dosages (up to 5 mg/10 mL/kg/d), a delayed tissue Wnt signaling suppression (max inhibition 7 to 10 h post dosing) is seen due to pre-existing Wnt in tissue, followed by a full recovery of tissue Wnt signalling at 24 h upon drug clearance. The periodic daily inhibition/recovering cycle is shown to result in tumor regression in mice & rats, while allowing Wnt signaling-dependent normal tissue homeostasis. Overdosing is reported to result in loss of intestinal epithelium in rats receiving 14 consecutive 20 mg/kg daily oral dosages.

Działania biochem./fizjol.

Cell permeable: yes

Primary Target
Porcupine

Reversible: yes

Opakowanie

Packaged under inert gas

Ostrzeżenie

Toxicity: Standard Handling (A)

Rekonstytucja

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Inne uwagi

Liu, J., et al. 2013. Proc. Natl. Acad. Sci. USA110, 20224.

Informacje prawne

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 11 - Combustible Solids
• Klasa zagrożenia wodnego (WGK): WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable